SCHEMBL1623329

SCHEMBL1623329

Cc1ccc(OCCNc2nc(Nc3cc(C4CC4)[nH]n3)cc(C)c2C#N)c(C)n1

nearest known ligand 0.79

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
AURKA O14965 12/20 0.79
CYP3A4 P08684 8/20 0.79
CYP2C9 P11712 4/20 0.79
CYP2C19 P33261 4/20 0.79
CYP1A2 P05177 5/20 0.63
CYP2D6 P10635 7/20 0.61
RAB29 O14966 1/20 0.59
FYN P06241 1/20 0.59
YES1 P07947 1/20 0.59
LYN P07948 1/20 0.59
FGFR1 P11362 1/20 0.59
SRC P12931 1/20 0.59
KDR P35968 1/20 0.59
AURKB Q96GD4 1/20 0.59
IGF1R P08069 5/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1623553 0.89 AURKA (1.00) AURKACYP3A4CYP2C9CYP2C19CYP1A2
Hydrochloric Acid SCHEMBL1623902 0.88 AURKA (0.98) AURKACYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL1622913 0.87 AURKA (0.78) AURKACYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL1623908 0.87 CYP3A4 (0.60) AURKACYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL1623897 0.86 AURKA (0.79) AURKACYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL1623613 0.86 AURKA (0.85) AURKACYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL1623205 0.85 AURKA (0.81) AURKACYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL12721013 0.85 CYP3A4 (0.57) AURKACYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL1623446 0.83 AURKA (0.79) AURKACYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL1623990 0.82 AURKA (0.75) AURKACYP3A4CYP2C9CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1876178-B1 CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2015-05-27 EP disclosed
US-7928126-B2 Cyanopyridine derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-04-19 US disclosed
US-7928126-B2 Cyanopyridine derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-04-19 US disclosed
US-20090292121-A1 Cyanopyridine derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-11-26 US disclosed
US-20090292121-A1 Cyanopyridine derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-11-26 US disclosed
EP-1876178-A1 CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2008-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292121-A1 Cyanopyridine derivative and use thereof as medicine DPYD, IDH1, TP53 AURKA 172/4885CYP3A4 177/4885CYP2C9 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.